Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease : An analysis from the platelet inhibition and patient outcomes (plato) trial
Background-Patients with chronic obstructive pulmonary disease (COPD) experiencing acute coronary syndromes (ACS) are at high risk for clinical events. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may l
